RS

Ranjana Sandiprao Khangar

Director Director DIN 08198848
DIN 08198848 First appointment Aug 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Aug 2018
Shareholding value •••• Premium profile

About Ranjana Sandiprao Khangar

Data last updated:

Ranjana Sandiprao Khangar was a Director at Zenovia Lifesciences Private Limited (2018–2019) and Designated Partner at Apex Multiedge Llp (2018–2022). The companies operate in Pharma and Business Services.

DIN 08198848
Primary Designation Director
Industry Pharma
First Appointment 12 Aug 2018

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Zenovia Lifesciences Private Limited U93000MH2017PTC295030
Director12 Aug 20182017Active
Designated Partner25 Sep 20182018Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Zenovia Lifesciences Private Limited
Apex Multiedge Llp
Premium access

Shareholding and investment profile for Ranjana Sandiprao Khangar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ranjana Sandiprao Khangar

Ranjana Sandiprao Khangar was first appointed on 12 Aug 2018 as Director at Zenovia Lifesciences Private Limited.

Ranjana Sandiprao Khangar held 2 earlier board appointments: Zenovia Lifesciences Private Limited (Director, 12 Aug 2018 to 21 Sep 2019); Apex Multiedge Llp (Designated Partner, 25 Sep 2018 to 09 Sep 2022).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available